Related Experiment Video
Updated: Apr 22, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Loss of p300/CBP-associated factor aggravates cardiac remodeling via regulation of CAMKK2 acetylation
Yongwoon Lim1,2,3, Anna Jeong1,2, Duk-Hwa Kwon1,2
1Department of Pharmacology, Chonnam National University Medical School, Hwasun, Republic of Korea.
Abstract:
Here we aim to elucidate the role of the p300/CBP-associated factor (PCAF) in pathological cardiac remodeling. Specifically, we explore how PCAF-mediated acetylation of calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) influences AMPK signaling, thereby regulating cardiac hypertrophy and dysfunction under pathological stress. A genetically engineered PCAF-knockout (KO) mouse model was generated using the CRISPR-Cas9 system to evaluate the effect of PCAF deficiency on cardiac remodeling induced by isoproterenol infusion and transverse aortic constriction (TAC). PCAF deficiency significantly aggravated cardiac enlargement with features of eccentric hypertrophy, as demonstrated by histological analysis and echocardiography. To determine these phenotypes were cardiomyocyte specific, we generated a cardiomyocyte-specific conditional KO model, which also showed a dilated cardiomyopathy-like phenotype similar to that of the global-KO mice. Transcriptomic analysis of TAC-operated hearts from wild-type and KO mice revealed enrichment of pathways related to mitochondrial function and energy homeostasis. Mechanistically, PCAF directly acetylated CAMKK2, promoting its activation and the subsequent phosphorylation of AMP-activated protein kinase α (AMPKα) at Thr172, a critical step in maintaining metabolic balance under stresses. These signaling alterations were also observed in the hearts of PCAF-KO hearts subjected to isoproterenol administration or TAC. Pharmacological activation of PCAF with SPV106 effectively attenuated TAC-induced cardiac remodeling, preserving cardiac structure and function. Collectively, these findings identify PCAF as a pivotal regulator of pathological cardiac remodeling through modulation of the CAMKK2-AMPK signaling axis. Loss of PCAF exacerbates stress-induced cardiac hypertrophy and dysfunction, highlighting its potential as a therapeutic target to preserve cardiac function and counteract stress-induced remodeling.
Insights
The p300/CBP-associated factor (PCAF) regulates cardiac remodeling by acetylating CAMKK2, influencing AMPK signaling. Loss of PCAF worsens cardiac hypertrophy and dysfunction under stress, indicating PCAF as a therapeutic target.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Epigenetics
Background:
- Pathological cardiac remodeling contributes to heart failure.
- The role of epigenetic modifiers like PCAF in cardiac stress response is not fully understood.
- Understanding molecular pathways is crucial for developing new therapies.
Purpose of the Study:
- To elucidate the role of p300/CBP-associated factor (PCAF) in pathological cardiac remodeling.
- To investigate how PCAF influences CAMKK2-AMPK signaling in the heart.
- To evaluate PCAF as a potential therapeutic target for cardiac dysfunction.
Main Methods:
- Generated global and cardiomyocyte-specific PCAF-knockout mouse models using CRISPR-Cas9.
- Induced cardiac remodeling via isoproterenol infusion and transverse aortic constriction (TAC).
- Performed histological analysis, echocardiography, and transcriptomic analysis.
Main Results:
- PCAF deficiency aggravated cardiac enlargement and eccentric hypertrophy in response to stress.
- PCAF directly acetylates CAMKK2, activating the CAMKK2-AMPKα signaling pathway.
- Pharmacological activation of PCAF attenuated TAC-induced cardiac remodeling.
Conclusions:
- PCAF is a key regulator of pathological cardiac remodeling via the CAMKK2-AMPK signaling axis.
- Loss of PCAF exacerbates stress-induced cardiac hypertrophy and dysfunction.
- Targeting PCAF may offer a novel therapeutic strategy for heart disease.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
05:04In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
cAMP-dependent Protein Kinase Pathways
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy IV: Restrictive Cardiomyopathy
Pathophysiology of Heart Failure